Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 3 | Nutrition & Metabolism

Fig. 3

From: Plasma acylcarnitines could predict prognosis and evaluate treatment of IgA nephropathy

Fig. 3

a ROC curve using baseline characteristics to predict treatment response (eGFR T2/T1 > =1.2) and non-response (eGFR T2/T1 < 1.2). b ROC curve using baseline characteristics to predict disease progress (eGFR T2/T1 < =0.8) and non-progress (eGFR T2/T1 > 0.8). c Baseline acyl-carnitines comparison in patients with progress (eGFR T2/T1 < =0.8) and non-progress (eGFR T2/T1 > 0.8)

Back to article page